<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517370</url>
  </required_header>
  <id_info>
    <org_study_id>0392-18-HMO</org_study_id>
    <nct_id>NCT04517370</nct_id>
  </id_info>
  <brief_title>CO2 Laser Therapy for the Treatment of GSM in Patients With Breast Cancer</brief_title>
  <official_title>CO2 Laser Therapy for the Treatment of GSM in Patients With Breast Cancer A Comparative, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the need for an effective, non-hormonal treatment for Genitourinary syndrome of&#xD;
      menopause GSM) symptoms in breast cancer survivors, the reported efficacy of fractional CO2&#xD;
      laser as such a treatment in retrospective studies, the study aims to evaluate the efficacy&#xD;
      of CO2 laser for the treatment of GSM in breast cancer patients, in a prospective,&#xD;
      randomized, blinded, placebo-controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in dryness</measure>
    <time_frame>Follow up after 3 treatments and at 1 month, 3 months and 6 months after last treatment.</time_frame>
    <description>Change in VAS before and after completion of treatment for dryness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in dyspareunia</measure>
    <time_frame>Follow up after 3 treatments and at 1 month, 3 months and 6 months after last treatment.</time_frame>
    <description>Change in VAS before and after completion of treatment for dyspareunia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Genitourinary Syndrome of Menopause</condition>
  <arm_group>
    <arm_group_label>Laser treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each patient will be treated once every 20-40 days, for a total of 3 laser treatments. In every visit during the study, patients will undergo gynecological examination and will complete questionnaires evaluating GSM symptoms, using a visual analogue scale (VAS) for each symptom (vaginal dryness, dyspareunia, discharge, itching and/or stinging, vaginal bleeding and dysuria) as well as treatment induced pain and side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Each patient will be treated once every 20-40 days, for a total of 3 Sham treatments, in a similar procedure not using an active laser energy. Patients will be assessed in a similar manner.&#xD;
Following 3 Sham-treatments patients in the placebo group will be offered the laser treatment in an open-label study .</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractional/Pixel CO2 laser</intervention_name>
    <description>The treatment is done with a specialized vaginal applicator which allows treatment of vagina, using the Femilift fractional micro ablative CO2 laser system (Alma Lasers, Israel), according to the usual protocol (Laser mode: Pulse, Energy: 40-80 mj/pulse).&#xD;
Before treatment, 5ml of topical anesthetic ointment (10% lidocaine in Vaseline base) will be spread in the vagina and on the vestibule for 30 minutes in both groups to avoid pain from the laser, as well as to allow the comparison between the groups (patients in both groups will not experience pain and therefore will remain blinded to their allocation).</description>
    <arm_group_label>Laser treatment</arm_group_label>
    <arm_group_label>Sham treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients diagnosed with breast cancer&#xD;
&#xD;
          2. Menopause: spontaneous, surgical or chemotherapy induced&#xD;
&#xD;
          3. One or more GSM Symptoms: dryness, irritation, burning, pain, dyspareunia, dysuria&#xD;
&#xD;
          4. On exam, clinical findings of atrophy: thin, dry, pale vagina&#xD;
&#xD;
          5. Age&gt;18&#xD;
&#xD;
          6. Normal Pap smear within 3 years&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Menstruation&#xD;
&#xD;
          2. Chemotherapy&#xD;
&#xD;
          3. Vaginal bleeding which did not underwent evaluation&#xD;
&#xD;
          4. Concurrent treatment with topical estrogen&#xD;
&#xD;
          5. Previous vulvar, vaginal or cervical dysplasia\ cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahinoam Lev-Sagie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahinoam Lev-Sagie, MD</last_name>
    <phone>+972244327278</phone>
    <email>levsagie@netvision.net.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ahinoam Lev-Sagie</name>
      <address>
        <city>Lapid</city>
        <zip>73133</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahinoam Lev-Sagie, MD</last_name>
      <phone>0544327178</phone>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 16, 2020</study_first_submitted>
  <study_first_submitted_qc>August 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 16, 2020</last_update_submitted>
  <last_update_submitted_qc>August 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

